Last edition
News about "Global Pharma Markets"
Emcure Reports Robust Q1 FY27 Results, PAT Surges 36 Percent
Emcure Pharmaceuticals reported a strong Q1 FY27 with 22.8 percent revenue growth, 36.2 percent higher profit, improved margins, robust performance across key therapies, and over 15 product approvals in global markets.
Global Pharma Markets | 07/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members